Amylyx Pharmaceuticals (AMLX) Other Accumulated Expenses (2021 - 2022)
Amylyx Pharmaceuticals (AMLX) posted quarterly Other Accumulated Expenses of $1.0 million for Q4 2022, up 289.53% year-over-year from $258000.0 in Q4 2021, and up 182.3% quarter-over-quarter from $356000.0 in Q3 2022.
Amylyx Pharmaceuticals (AMLX) Other Accumulated Expenses (2021 - 2022) Analysis & Trends
Amylyx Pharmaceuticals' Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $1.0 million for Q4 2022.
- In Q4 2022, Other Accumulated Expenses rose 289.53% year-over-year to $1.0 million; the TTM figure through Dec 2022 stood at $1.0 million (up 289.53% YoY), while the FY2022 annual figure was $1.0 million, up 289.53% from the prior year.
- Other Accumulated Expenses for Q4 2022 stood at $1.0 million, up from $356000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $1.0 million in Q4 2022, with the low at $258000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Amylyx Pharmaceuticals | 4.41 Bn | 4.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.01 Mn |
| Sep 30, 2022 | 356,000.00 |
| Jun 30, 2022 | 535,000.00 |
| Mar 31, 2022 | 439,000.00 |
| Dec 31, 2021 | 258,000.00 |